Abstract：
Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy or with a kidney transplant. Since the publication of the Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2018, advances in HCV management, particularly in the field of antiviral therapy and treatment of HCV-associated glomerular diseases, coupled with increased usage of HCV-positive kidney grafts, have prompted a reexamination of the 2018 guideline. As a result, the Work Group performed a comprehensive review and revised the 2018 guidance. This Executive Summary highlights key aspects of the updated guideline recommendations for 3 chapters: Chapter 2: Treatment of HCV infection in patients with CKD; Chapter 4: Management of HCV-infected patients before and after kidney transplantation; and Chapter 5: Diagnosis and management of kidney diseases associated with HCV infection.
摘要：
感染丙型肝炎病毒（HCV）有不良的肝脏，肾,慢性肾脏病（CKD）患者的心血管后果，包括接受透析治疗或肾移植的患者.自2018年肾脏疾病：改善全球结果（KDIGO）HCV指南发布以来，HCV管理的进展，特别是在抗病毒治疗和HCV相关肾小球疾病的治疗领域，再加上HCV阳性肾移植的使用增加，促使人们重新审视2018年的指导方针。因此,工作组进行了全面审查并修订了2018年指南.本执行摘要重点介绍了3章更新指南建议的关键方面：第2章：CKD患者HCV感染的治疗；第4章：肾移植前后HCV感染患者的管理；第5章：与HCV感染相关的肾脏疾病的诊断和管理。
